Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

Table of Contents

September 1, 2017; Volume 58,Issue 9

Cover image

Cover image expansion

FEATURED ARTICLE

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Steve Cho et al. See page 1421.

Can PET/CT predict response to immune checkpoint blockade in melanoma? James Kelly et al. See page 1442.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 58 (9)
Journal of Nuclear Medicine
Vol. 58, Issue 9
September 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
  • Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
  • Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?
  • Operational and Dosimetric Aspects of Pediatric PET/CT
Sign up for alerts

Jump to

  • This Month in JNM
  • Hot Topics
  • Continuing Education
  • Focus on Molecular Imaging
  • Oncology
    • Basic
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
  • Theranostics
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
    • Clinical
      • INVITED PERSPECTIVE
  • Cardiology
    • Clinical
  • Neurology
    • Translational
    • Clinical
  • Radiation Biology
  • Inflammation/Infectious Disease
  • Physics/Instrumentation
  • Book Reviews
  • Letters to the Editor
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
  • Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
  • Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
  • Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
  • 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire